FutureChem Co.Ltd - Asset Resilience Ratio
FutureChem Co.Ltd (220100) has an Asset Resilience Ratio of 38.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 220100 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how FutureChem Co.Ltd's Asset Resilience Ratio has changed over time. See how leveraged is FutureChem Co.Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down FutureChem Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 220100 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩27.29 Billion | 38.83% |
| Total Liquid Assets | ₩27.29 Billion | 38.83% |
Asset Resilience Insights
- Very High Liquidity: FutureChem Co.Ltd maintains exceptional liquid asset reserves at 38.83% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
FutureChem Co.Ltd Industry Peers by Asset Resilience Ratio
Compare FutureChem Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for FutureChem Co.Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for FutureChem Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.84% | ₩27.42 Billion ≈ $18.58 Million |
₩74.42 Billion ≈ $50.43 Million |
+13.02pp |
| 2023-12-31 | 23.82% | ₩17.35 Billion ≈ $11.76 Million |
₩72.83 Billion ≈ $49.36 Million |
-18.50pp |
| 2022-12-31 | 42.31% | ₩37.54 Billion ≈ $25.44 Million |
₩88.72 Billion ≈ $60.12 Million |
+4.64pp |
| 2021-12-31 | 37.67% | ₩29.06 Billion ≈ $19.69 Million |
₩77.14 Billion ≈ $52.27 Million |
-14.26pp |
| 2020-12-31 | 51.93% | ₩42.82 Billion ≈ $29.02 Million |
₩82.46 Billion ≈ $55.88 Million |
+48.14pp |
| 2019-12-31 | 3.79% | ₩2.40 Billion ≈ $1.62 Million |
₩63.21 Billion ≈ $42.84 Million |
-55.97pp |
| 2018-12-31 | 59.76% | ₩38.28 Billion ≈ $25.94 Million |
₩64.05 Billion ≈ $43.40 Million |
+28.78pp |
| 2017-12-31 | 30.98% | ₩11.15 Billion ≈ $7.56 Million |
₩36.00 Billion ≈ $24.40 Million |
+12.86pp |
| 2016-12-31 | 18.12% | ₩6.00 Billion ≈ $4.07 Million |
₩33.11 Billion ≈ $22.44 Million |
-- |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more